George R. Painter

7.2k total citations · 3 hit papers
98 papers, 3.9k citations indexed

About

George R. Painter is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, George R. Painter has authored 98 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Infectious Diseases, 48 papers in Epidemiology and 36 papers in Virology. Recurrent topics in George R. Painter's work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (21 papers) and Herpesvirus Infections and Treatments (17 papers). George R. Painter is often cited by papers focused on HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (21 papers) and Herpesvirus Infections and Treatments (17 papers). George R. Painter collaborates with scholars based in United States, United Kingdom and Germany. George R. Painter's co-authors include Michael G. Natchus, Wendy Painter, Alice Robertson, Alexander A. Kolykhalov, Karl Y. Hostetler, Gregory R. Bluemling, Bernhard Lampert, Berton C. Pressman, Lawrence C. Trost and R. Mark L. Buller and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

George R. Painter

96 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

2021 274 citations Wendy Painter, Wayne Holman et al. profile →
Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

2019 255 citations Maria L. Agostini, Andrea J. Pruijssers et al. Journal of Virology profile →
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

2019 233 citations Märt Toots, Jeong-Joong Yoon et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
George R. Painter United States	36	2.1k	1.6k	1.1k	1.0k	383	98	3.9k
Luis Menéndez‐Arias Spain	38	2.4k 1.1×	683 0.4×	1.9k 1.6×	2.1k 2.0×	348 0.9×	143	4.6k
Matthias Götte Canada	40	4.2k 2.0×	1.2k 0.7×	2.1k 1.8×	1.8k 1.8×	254 0.7×	138	6.1k
Akhteruzzaman Molla United States	38	2.4k 1.1×	1.1k 0.6×	1.3k 1.1×	1.4k 1.4×	214 0.6×	85	4.6k
Bo Öberg Sweden	28	1.2k 0.6×	1.1k 0.6×	878 0.8×	745 0.7×	141 0.4×	76	2.8k
J. M. Cameron United Kingdom	23	1.8k 0.8×	1.7k 1.0×	1.5k 1.3×	1.3k 1.3×	257 0.7×	35	3.9k
Joy Y. Feng United States	30	5.2k 2.4×	822 0.5×	1.4k 1.3×	732 0.7×	144 0.4×	67	6.6k
Dirk Jochmans Belgium	32	3.1k 1.5×	750 0.5×	930 0.8×	1.1k 1.1×	163 0.4×	94	4.3k
Jon H. Condra United States	27	3.4k 1.6×	1.0k 0.6×	1.1k 0.9×	3.2k 3.1×	237 0.6×	47	5.1k
Mark N. Prichard United States	39	1.1k 0.5×	3.5k 2.1×	1.4k 1.2×	837 0.8×	492 1.3×	143	5.4k
Xiaojian Yao Canada	34	1.8k 0.8×	752 0.5×	1.4k 1.2×	2.3k 2.2×	274 0.7×	95	3.6k

Countries citing papers authored by George R. Painter

Since Specialization

Citations

This map shows the geographic impact of George R. Painter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George R. Painter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George R. Painter more than expected).

Fields of papers citing papers by George R. Painter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George R. Painter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George R. Painter. The network helps show where George R. Painter may publish in the future.

Co-authorship network of co-authors of George R. Painter

This figure shows the co-authorship network connecting the top 25 collaborators of George R. Painter. A scholar is included among the top collaborators of George R. Painter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George R. Painter. George R. Painter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chawla, Akshita, Ruthie Birger, Brian M. Maas, et al.. (2025). Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19. Clinical and Translational Science. 18(4). e70184–e70184.

Westover, Jonna B., Kevin W. Bailey, Alexander A. Kolykhalov, et al.. (2025). Effective treatment of advanced Oropouche virus, Rift Valley fever virus, and Dabie bandavirus infections with 4'-fluorouridine. mBio. 16(10). e0146725–e0146725.

Cox, Robert M., Carolin M. Lieber, Josef D. Wolf, et al.. (2023). Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Nature Communications. 14(1). 4731–4731. 18 indexed citations

Bluemling, Gregory R., Michael G. Natchus, Wendy Painter, et al.. (2022). The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection. Antiviral Research. 209. 105453–105453. 9 indexed citations

Painter, George R., et al.. (2021). Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Current Opinion in Virology. 50. 17–22. 112 indexed citations

Toots, Märt, Jeong-Joong Yoon, Robert M. Cox, et al.. (2019). Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine. 11(515). 233 indexed citations breakdown →

Painter, George R., Richard A. Bowen, Gregory R. Bluemling, et al.. (2019). The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Research. 171. 104597–104597. 81 indexed citations

Agostini, Maria L., Andrea J. Pruijssers, James D. Chappell, et al.. (2019). Small-Molecule Antiviral β- d - N ⁴ -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. Journal of Virology. 93(24). 255 indexed citations breakdown →

Urakova, Nadya, Valeriya Kuznetsova, David K. Crossman, et al.. (2017). β- d - N ⁴ -Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome. Journal of Virology. 92(3). 148 indexed citations

10.

Welch, Stephen R., Lisa Wiggleton Guerrero, Ayan K. Chakrabarti, et al.. (2016). Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. Antiviral Research. 136. 9–18. 57 indexed citations

11.

Rice, Amanda D., Mathew M. Adams, Bernhard Lampert, et al.. (2011). Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses. 3(2). 63–82. 36 indexed citations

12.

Quenelle, Debra C., et al.. (2010). Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies. The Journal of Infectious Diseases. 202(10). 1492–1499. 61 indexed citations

13.

Clair, M H St, Judith Millard, John P. Rooney, et al.. (1996). In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Research. 29(1). 53–56. 65 indexed citations

14.

Wright, Lois L., et al.. (1996). Recombinant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Is Heterogeneous. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 11(1). 20–30. 6 indexed citations

15.

Painter, George R., et al.. (1995). 524W91. Anti-HIV, Anti-hepatitis B virus. Drugs of the Future. 20(8). 761–765. 5 indexed citations

16.

Pazhanisamy, S., et al.. (1995). Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy. The Journal of Infectious Diseases. 172(5). 1238–1245. 63 indexed citations

17.

Cheng, Nancy, B M Merrill, George R. Painter, Lloyd Frick, & Phillip A. Furman. (1993). Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label. Biochemistry. 32(30). 7630–7634. 23 indexed citations

18.

Painter, George R., Ann Aulabaugh, & C. Webster Andrews. (1993). A Comparison of the Conformations of the 5′-Triphosphates of Zidovudine (AZT) and Thymidine Bound to HIV-1 Reverse Transcriptase. Biochemical and Biophysical Research Communications. 191(3). 1166–1171. 31 indexed citations

19.

Cheng, Nancy, George R. Painter, & Phillip A. Furman. (1991). Crosslinking of substrates occurs exclusively to the p66 subunit of heterodimeric HIV-1 reverse transcriptase. Biochemical and Biophysical Research Communications. 174(2). 785–789. 35 indexed citations

20.

Painter, George R., et al.. (1990). The effects of lipid composition on the binding of lasalocid A to small unilamellar vesicles. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1027(3). 245–252. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact